Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
INOVIQ Ltd (IIQ.AX)
Notting Hill, VIC, AU
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.56% | +1.56% | +0.00% | -7.14% | -8.45% | -16.13% | -26.14% | -30.85% | -84.52% | -62.78% | -99.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+239.2% ★ Q4'25: +127.7% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+12.1% Q4'25: +5.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-360.0% Q4'25: -965.9% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-404.6% Q4'25: -2,183.5% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-69.5% Q4'25: -187.7% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+20.3% Q4'25: +32.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.06× Q4'25: -0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 2 EPS Ana. |
Jun 2027 2 Rev. Ana. 2 EPS Ana. |
Jun 2028 2 Rev. Ana. 2 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
276.7K
est: 300.0K (-7.8%)
|
398.2K
est: 400.0K (-0.5%)
|
535.1K
est: 900.0K (-40.5%)
|
1.82M
est: 500.0K (+263.1%)
|
900.0K
811.8K – 988.2K
+80.0% YoY
|
1.90M
1.61M – 2.19M
+111.1% YoY
|
5.50M
4.96M – 6.04M
+189.5% YoY
|
5.40M
4.87M – 5.93M
-1.8% YoY
|
50.10M
45.19M – 55.01M
+827.8% YoY
|
| EBITDA |
-19.39M
est: -300.0K (-6,362.5%)
|
-9.32M
est: -400.0K (-2,230.5%)
|
-6.34M
est: -900.0K (-604.0%)
|
-6.16M
est: -500.0K (-1,131.5%)
|
-900.0K
-988.2K – -811.8K
-80.0% YoY
|
-1.90M
-2.19M – -1.61M
-111.1% YoY
|
-5.50M
-6.04M – -4.96M
-189.5% YoY
|
-5.40M
-5.93M – -4.87M
+1.8% YoY
|
-50.10M
-55.01M – -45.19M
-827.8% YoY
|
| EBIT |
-21.49M
est: -300.0K (-7,063.0%)
|
-10.48M
est: -400.0K (-2,519.0%)
|
-7.54M
est: -900.0K (-737.8%)
|
-7.34M
est: -500.0K (-1,368.8%)
|
-900.0K
-988.2K – -811.8K
-80.0% YoY
|
-1.90M
-2.19M – -1.61M
-111.1% YoY
|
-5.50M
-6.04M – -4.96M
-189.5% YoY
|
-5.40M
-5.93M – -4.87M
+1.8% YoY
|
-50.10M
-55.01M – -45.19M
-827.8% YoY
|
| Net Income |
-18.20M
est: -11.12M (-63.6%)
|
-8.97M
est: -11.90M (+24.6%)
|
-6.55M
est: -10.90M (+39.9%)
|
-6.93M
est: -8.01M (+13.4%)
|
-8.40M
-10.88M – -5.80M
-4.9% YoY
|
-7.23M
-8.95M – -5.51M
+13.9% YoY
|
-7.60M
-13.49M – 2.81M
-5.1% YoY
|
-2.22M
-2.51M – -1.94M
+70.7% YoY
|
23.35M
20.38M – 26.33M
+1,150.0% YoY
|
| SGA |
4.43M
est: 2.90M (+52.8%)
|
7.61M
est: 3.86M (+96.8%)
|
3.64M
est: 8.69M (-58.1%)
|
5.78M
est: 4.83M (+19.8%)
|
8.69M
7.84M – 9.55M
+80.0% YoY
|
18.35M
15.57M – 21.14M
+111.1% YoY
|
53.13M
47.92M – 58.34M
+189.5% YoY
|
52.17M
47.05M – 57.28M
-1.8% YoY
|
483.99M
436.54M – 531.44M
+827.8% YoY
|
| EPS |
-0.20
est: -0.10 (-100.0%)
|
-0.10
est: -0.11 (+8.9%)
|
-0.07
est: -0.10 (+27.7%)
|
-0.06
est: -0.07 (+13.5%)
|
-0.08
-0.10 – -0.05
-4.2% YoY
|
-0.07
-0.08 – -0.05
+13.3% YoY
|
-0.05
-0.12 – 0.03
+26.2% YoY
|
-0.02
-0.02 – -0.02
+58.3% YoY
|
0.21
0.18 – 0.24
+1,150.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Leearne Maree Hinch | Chief Executive Officer | 560.5K | — |
| Mark Edwards BACC | Chief Financial Officer & Company Secretary | 337.1K | male |
| Rebecca Lim | Chief Scientific Officer | 278.9K | female |
| Emma Ball | Chief Commercial Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IIQ.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
